Clinical Trial Update: Efficacy, Safety, and Tolerability of Perhexiline in Subjects With Hypertrophic Cardiomyopathy and Heart Failure [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating perhexiline for hypertrophic cardiomyopathy with heart failure has been withdrawn, with study data not advancing to completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure
• Hypertrophic Cardiomyopathy

Drugs mentioned

• Perhexiline (perhexiline)

Snippet

Sponsor: Heart Metabolics Limited | Conditions: Hypertrophic Cardiomyopathy | Phase 3 | Status: WITHDRAWN